Trial Profile
A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AMPLITUDE-S
- Sponsors Sanofi
- 20 Jul 2023 Results from three phase 3 studies: AMPLITUDE-D, AMPLITUDE-S, and AMPLITUDE-L reporting efficacy and safety data published in the Diabetes, Obesity and Metabolism
- 06 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 15 Sep 2020 Status changed from recruiting to active, no longer recruiting.